FDA drug center head expected to leave after commissioner's exit, sources say
Her exit follows Makary’s resignation and adds to a broader FDA leadership shake-up that has already prompted multiple high-level departures, officials said.
- On Friday, the FDA announced that Tracy Beth Hoeg is stepping down as acting drug center director, with Mike Davis, the center's deputy director, replacing her.
- Hoeg's departure marks the latest transition in an ongoing shake-up at the FDA, following FDA Commissioner Marty Makary's resignation earlier this week and Vinay Prasad's departure last month.
- During her tenure, Hoeg conducted an "initial analysis" linking COVID-19 vaccines to 10 reported deaths in children without providing evidence, while remaining closely aligned with Makary and Health Secretary Robert.
- The agency also announced Friday that Karim Mikhail, a longtime pharmaceutical executive hired by Makary last spring, will assume the role of acting vaccines center director.
- Hoeg's exit underscores a revolving door of leadership changes at the agency, where recent appointees including her lacked the decades of career scientific experience typically required for center director positions.
132 Articles
132 Articles
The acting director of the US Food and Drug Administration's (FDA) Center for Drug Enforcement Administration, Tracy Beth Hagg, was removed on Friday.
Second FDA executive departing organization in less than a week as top drug regulator claims she was fired
Dr. Tracy Beth Høeg, former acting director of the Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER), became the second high-ranking official to depart the FDA this week after claiming she was fired Friday.Høeg's departure came after that of former FDA Commissioner Dr. Marty Makary, who publicly resigned Tuesday after rumors that President Donald Trump was unhappy with him swirled for days.Høeg, who worked close…
6 reactions to Marty Makary resigning from FDA after e-cig, abortion pill tensions
Marty Makary’s resignation as commissioner of the FDA comes amid reported tensions over e-cigarette regulations and criticism from pro-life advocacy groups accusing him of delaying a safety review of the abortion pill. Here are six reactions to Makary's resignation.
Acting FDA commissioner promises transparency, action on abortion pill * WorldNetDaily * by Elizabeth Troutman Mitchell, The Daily Signal
Source link The acting commissioner of the Food and Drug Administration has promised to prioritize a safety review of the abortion pill after his predecessor was accused of delaying it, pro-life leaders say. Kyle Diamantas, FDA deputy commissioner for food, is serving as acting FDA commissioner in the wake of Dr. Marty Makary’s departure. Though the
Coverage Details
Bias Distribution
- 62% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
